Popular Pre-Market Trades in U.S. Stocks
Evoke Pharma is down 7.89% in pre-market trading. Based on recent important news:
<ol>
<li>
On July 9, Evoke Pharma released information through EDGAR, leading to increased stock price volatility.
</li>
<li>
On July 10, Evoke Pharma obtained a new patent for GIMOTI, causing the stock price to rise.
</li>
<li>
Recently, the U.S. pharmaceutical industry is facing policy uncertainties, affecting stock prices.
</li>
</ol>
Top Gainers in Pre-Market Trading in U.S. Stocks
GlucoTrack is up 73.06% in pre-market trading. Based on recent key news:
<ol>
<li>
On June 25, GlucoTrack announced that its new non-invasive blood glucose monitoring device received FDA approval, resulting in a positive market reaction and a significant stock price increase.
</li>
<li>
On June 26, GlucoTrack signed a strategic cooperation agreement with a large medical device company, further boosting market confidence and driving the stock price up.
</li>
<li>
On June 27, a well-known analyst raised GlucoTrack's target price, expecting a significant increase in its market share, leading to a corresponding rise in stock price.
</li>
</ol>
Helius Medical Tech is up 70.67% in pre-market trading. Based on recent important news:
<ol>
<li>
On July 21, Helius announced positive results from its portable neurostimulation device PONS® stroke registration program and plans to submit a breakthrough designation application to the FDA in the third quarter of 2025, significantly boosting the stock price.
</li>
<li>
On July 21, Helius confirmed that studies on PONS treatment showed very few adverse events, enhancing market confidence.
</li>
<li>
On July 21, news of Helius's plans to submit an FDA application further stimulated investor optimism.
</li>
</ol>
reAlpha Tech is up 39.21% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 16, reAlpha Tech announced a 4432% year-over-year revenue growth for the quarter ending March 31, leading to a surge in stock price.
</li>
<li>
On July 16, reAlpha Tech announced a $2 million public offering, causing the stock price to drop by 25.7%.
</li>
<li>
On July 17, reAlpha Tech's public offering was priced at $0.15 per share, and the stock price continued to decline
</li>
</ol>

EVOK

Evoke Pharma pre-market down 7.89%; GlucoTrack pre-market up 73.06%; Helius Medical Tech pre-market up 70.67%; reAlpha Tech pre-market up 39.21%

Pre-market hot trades in US stocks: Evoke Pharma pre-market down 7.89%